American Association for Cancer Research
10780432ccr200894-sup-238866_2_supp_6623606_qhmmxk.pdf (452.72 kB)

Supplementary Data from Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice

Download (452.72 kB)
journal contribution
posted on 2023-03-31, 22:34 authored by Pierre Montay-Gruel, Munjal M. Acharya, Patrik Gonçalves Jorge, Benoît Petit, Ioannis G. Petridis, Philippe Fuchs, Ron Leavitt, Kristoffer Petersson, Maude Gondré, Jonathan Ollivier, Raphael Moeckli, François Bochud, Claude Bailat, Jean Bourhis, Jean-François Germond, Charles L. Limoli, Marie-Catherine Vozenin

Supplementary Figure 1: Tumor growth delay of U87 orthotopic GBM implanted in the striatum of female Nude mice measured by contrast-enhanced Cone Beam CT



ISREC Foundation



Ecole Normale Supérieure de Cachan



Recent data have shown that single-fraction irradiation delivered to the whole brain in less than tenths of a second using FLASH radiotherapy (FLASH-RT), does not elicit neurocognitive deficits in mice. This observation has important clinical implications for the management of invasive and treatment-resistant brain tumors that involves relatively large irradiation volumes with high cytotoxic doses. Therefore, we aimed at simultaneously investigating the antitumor efficacy and neuroprotective benefits of FLASH-RT 1-month after exposure, using a well-characterized murine orthotopic glioblastoma model. As fractionated regimens of radiotherapy are the standard of care for glioblastoma treatment, we incorporated dose fractionation to simultaneously validate the neuroprotective effects and optimized tumor treatments with FLASH-RT. The capability of FLASH-RT to minimize the induction of radiation-induced brain toxicities has been attributed to the reduction of reactive oxygen species, casting some concern that this might translate to a possible loss of antitumor efficacy. Our study shows that FLASH and CONV-RT are isoefficient in delaying glioblastoma growth for all tested regimens. Furthermore, only FLASH-RT was found to significantly spare radiation-induced cognitive deficits in learning and memory in tumor-bearing animals after the delivery of large neurotoxic single dose or hypofractionated regimens. The present results show that FLASH-RT delivered with hypofractionated regimens is able to spare the normal brain from radiation-induced toxicities without compromising tumor cure. This exciting capability provides an initial framework for future clinical applications of FLASH-RT.See related commentary by Huang and Mendonca, p. 662

Usage metrics

    Clinical Cancer Research



    Ref. manager